Sign In
Buy GTHX
$7.15
+0 (+0%)
At Close: Dec 16, 2024
G1 Therapeutics to Participate Virtually in the 2022 BTIG Biotechnology Conference and the 2022 Wedbush Pacgrow Healthcare Conference
01:00pm, Monday, 01'st Aug 2022 GlobeNewswire Inc.
RESEARCH TRIANGLE PARK, N.C., Aug. 01, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that the Company will participate in two up
Analysts Estimate Vir Biotechnology, Inc. (VIR) to Report a Decline in Earnings: What to Look Out for
02:03pm, Thursday, 28'th Jul 2022 Zacks Investment Research
Vir Biotechnology, Inc. (VIR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate G1 Therapeutics (GTHX) to Report a Decline in Earnings: What to Look Out for
02:02pm, Wednesday, 27'th Jul 2022 Zacks Investment Research
G1 Therapeutics (GTHX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
G1 Therapeutics Announces Addition of Norman E. Sharpless to Board of Directors
10:30am, Monday, 25'th Jul 2022 GlobeNewswire Inc.
RESEARCH TRIANGLE PARK, N.C., July 25, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the appointment of Norman E. “Ned” Shar
G1 Therapeutics: Take Advantage Of The November Data
06:16am, Friday, 22'nd Jul 2022
GTHX will topline the mCRC phase 3 trial in November. This will help expand its label and increase revenues.
G1 Therapeutics to Release Second Quarter 2022 Financial Results and Provide Business Update on August 3, 2022
01:00pm, Wednesday, 20'th Jul 2022 GlobeNewswire Inc.
RESEARCH TRIANGLE PARK, N.C., July 20, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, will host a webcast and conference call to provide a corpor
G1 Therapeutics to Release Second Quarter 2022 Financial Results and Provide Business Update on August 3, 2022
09:00am, Wednesday, 20'th Jul 2022
RESEARCH TRIANGLE PARK, N.C., July 20, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, will host a webcast and conference call to provide a corporat
COSELA® (Trilaciclib Hydrochloride for Injection) Now Approved in China to Decrease the Incidence of Chemotherapy-Induced Myelosuppression in Patients with Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
02:15pm, Wednesday, 13'th Jul 2022 GlobeNewswire Inc.
RESEARCH TRIANGLE PARK, N.C., July 13, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that the China National Medical Products Ad
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
09:20pm, Friday, 01'st Jul 2022 GlobeNewswire Inc.
RESEARCH TRIANGLE PARK, N.C., July 01, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the grant of inducement stock options exerc
Got $500? 3 Absurdly Cheap Healthcare Stocks That Are Set to Skyrocket
08:45pm, Friday, 01'st Jul 2022 The Motley Fool
Here's why these Fool.com contributors are bullish on Adaptimmune Therapeutics, G1 Therapeutics, and Axsome Therapeutics.
Got $500? 3 Absurdly Cheap Healthcare Stocks That Are Set to Skyrocket
04:45pm, Friday, 01'st Jul 2022
Here's why these Fool.com contributors are bullish on Adaptimmune Therapeutics, G1 Therapeutics, and Axsome Therapeutics.
G1 Therapeutics Announces Addition of Jacks Lee to Board of Directors
11:30am, Tuesday, 28'th Jun 2022 GlobeNewswire Inc.
RESEARCH TRIANGLE PARK, N.C., June 28, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the appointment of Jacks Lee to its Board o
- Patients Receiving Trilaciclib Experienced a Lower Incidence of Single-Lineage and Multilineage Chemotherapy-Induced Myelosuppressive Events Compared with Patients Receiving Placebo -
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
08:45pm, Wednesday, 01'st Jun 2022 GlobeNewswire Inc.
RESEARCH TRIANGLE PARK, N.C., June 01, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the grant of inducement stock options exerc
G1 Therapeutics Named 2022 Life Sciences Public Company of the Year by Triangle Business Journal
02:30pm, Friday, 20'th May 2022 GlobeNewswire Inc.
RESEARCH TRIANGLE PARK, N.C., May 20, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that it received Triangle Business Journal'
